Adial Pharmaceuticals announced on September 3, 2025, that it has been granted a 180-calendar day extension by The Nasdaq Stock Market LLC. This extension is to regain compliance with Nasdaq's minimum $1.00 bid price requirement, set forth in Nasdaq Listing Rule 5550(a)(2).
The initial 180-calendar day period to regain compliance expired on September 1, 2025. With this extension, the company now has until March 2, 2026, to meet the Minimum Bid Price Requirement.
The notification has no immediate effect on the listing or trading of the company’s common stock, which will continue to trade on the Nasdaq Capital Market under the symbol “ADIL.” Adial intends to monitor its stock price and take appropriate actions to cure the deficiency before the new deadline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.